Robert Lutz was appointed as Chief Financial and Operating Officer at Savara Inc.
“On June 5, 2026, the Board appointed Robert Lutz to become the Chief Financial and Operating Officer of Savara effective July 15, 2026 (the "Effective Date").”
Savara Inc — fact timeline
Source-grounded facts extracted from Savara Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
David Lowrance departed as Chief Financial and Administrative Officer at Savara Inc.
“Mr. Lutz's appointment follows the decision of David Lowrance to resign from his role as Savara's Chief Financial and Administrative Officer, effective as of the Effective Date, due to health reasons.”
Savara Inc: Increased authorized shares of common stock from 300,000,000 to 600,000,000 (effective 2026-06-04).
“On June 4, 2026, the stockholders of Savara approved an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock of Savara from 300,000,000 to 600,000,000 (the “Amendment”). We filed the Amendment on June 4, 2026 with the Secretary of State of the State of Delaware, and the Amendment became effective upon filing.”
Savara Inc shareholders approved Proposal to approve, on an advisory basis, the compensation of our named executives. at the 2026-06-04 meeting.
“4. Proposal to approve, on an advisory basis, the compensation of our named executives. Votes For Votes Against Abstentions Broker Non Votes 156,706,529 2,307,296 195,253 24,628,938”
Savara Inc shareholders approved Proposal to ratify the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-04 meeting.
“3. Proposal to ratify the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions Broker Non Votes 183,558,080 231,887 48,049 —”
Savara Inc shareholders approved Proposal to approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 300,000,000 to 600,000,000. at the 2026-06-04 meeting.
“1. Proposal to approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 300,000,000 to 600,000,000. Votes For Votes Against Abstentions Broker Non Votes 176,809,841 6,847,631 180,544 —”
Savara Inc shareholders approved Election of Directors at the 2026-06-04 meeting.
“At the Savara annual meeting of stockholders held on June 4, 2026 (the “Annual Meeting”), our stockholders elected each of the following individuals to serve on the Board of Directors until the next annual meeting of stockholders, or until his or her successor is duly elected and qualified. Nominees Votes For Votes Against Abstentions Broker Non Votes Matthew Pauls 156,349,041 2,798,767 61,270 24,628,938 Nevan Elam 156,249,008 2,898,802 61,268 24,628,938 Richard J. Hawkins 156,794,295 2,352,624 62,159 24,628,938 Joseph S. McCracken 150,211,353 8,937,566 60,159 24,628,938 David A. Ramsay 156,218,095 2,754,776 236,207 24,628,938 An van Es-Johansson 158,694,187 460,731 54,160 24,628,938”
Savara Inc entered into "Agreement of Lease" with ML7 Yardley Partners, LP valued at approximately $1,780,900 (effective 2026-03-10).
“On March 10, 2026, Savara Inc. (the “Company”) entered into an Agreement of Lease (the “Lease”) with ML7 Yardley Partners, LP (“Landlord”), pursuant to which the Company will lease approximately 10,795 square feet of office space located at 19 W. College Avenue, Suite 200, Yardley, PA 19067.”
Savara Inc amended First Amendment with lenders party thereto and Hercules Capital, Inc., as administrative agent and collateral agent valued at up to an aggregate of $105 million of term loans (effective 2026-01-26).
“On January 26, 2026, Savara Inc. (the “Company”) entered into a First Amendment (the “First Amendment”) to the Loan and Security Agreement, dated March 26, 2025 (the “Loan Agreement”), with the lenders party thereto (the “Lenders”) and Hercules Capital, Inc., as administrative agent and collateral agent.”
Savara Inc incurred term loan of up to $200 million with Hercules Capital, Inc. at greater of (a) the prime rate reported in The Wall Street Journal or (b) 6.0%, p maturing April 1, 2030.
“party thereto (the “Lenders”) and Hercules Capital, Inc., as administrative agent and collateral agent (the “Agent”). The Loan Agreement provides for the Company to borrow up to $200 million of term loans (the “Term Loan”) that may be advanced in multiple tranches. The initial advance of $30 million under the Loan Agreement was drawn on the Closing Date and used to”
Dr. Ricky Sun departed as Director at Savara Inc.
“On April 10, 2024, Dr. Ricky Sun notified the Board of Directors (the “Board”) of Savara Inc. (the “Company”) of his intention not to stand for reelection to the Board following the expiration of his current term at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”).”
Savara Inc entered into Master Services Agreement with Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. (collectively, “Fujifilm”) (effective 2024-02-13).
“On February 13, 2024, Savara Inc. (the “Company”) entered into a Master Services Agreement (the “Agreement”) with Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. (collectively, “Fujifilm”), pursuant to which Fujifilm will continue to provide development and manufacturing services related to active pharmaceutical ingredient for the Company’s molgramostim product candidate in accordance with the terms of separate scope of work agreements to be entered into by the parties.”
Savara Inc entered into Underwriting Agreement with Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (effective 2023-07-12).
“On July 12, 2023, Savara Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell (i) an aggregate of 21,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) pre-funded warrants to purchase an aggregate of 5,666,667 shares of Common Stock with an exercise price of $0.001 per share (the “Pre-Funded Warrants”), to the Underwriters in an underwritten offering (the “Offering”).”
Savara Inc shareholders approved Proposal to approve, on an advisory basis, the compensation of our named executives. at the 2023-06-08 meeting.
“3. Proposal to approve, on an advisory basis, the compensation of our named executives. Votes For Votes Against Abstentions Broker Non Votes 79,056,687 3,316,098 4,715,242 10,006,793”
Savara Inc shareholders approved Proposal to ratify the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-08 meeting.
“2. Proposal to ratify the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions Broker Non Votes 91,958,455 429,981 4,706,384 —”
Savara Inc shareholders approved Proposal to approve the amendment of our 2015 Plan to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000. at the 2023-06-08 meeting.
“1. Proposal to approve the amendment of our 2015 Plan to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000. Votes For Votes Against Abstentions Broker Non Votes 81,912,831 468,273 4,706,923 10,006,793”
Savara Inc shareholders approved Election of Directors at the 2023-06-08 meeting.
“At the Savara Inc. annual meeting of stockholders held on June 8, 2023 (the “Annual Meeting”), our stockholders elected each of the following individuals to serve on the Board of Directors until the next annual meeting of stockholders, or until his or her successor is duly elected and qualified. Nominees Votes For Votes Against Abstentions Broker Non Votes Matthew Pauls 82,065,393 315,174 4,707,460 10,006,793 Nevan Elam 66,694,408 15,686,279 4,707,340 10,006,793 Richard J. Hawkins 66,220,852 16,158,043 4,709,132 10,006,793 Joseph S. McCracken 77,796,441 4,582,137 4,709,449 10,006,793 David A. Ramsay 81,975,464 403,205 4,709,358 10,006,793 Ricky Sun 81,677,611 701,220 4,709,196 10,006,793 An van Es-Johansson 82,153,500 226,705 4,707,822 10,006,793”
Savara Inc: Adopted Amended and Restated Bylaws with updates including stockholder proposal procedures, director nomination requirements, universal proxy rules, electronic notice, name change, written consent, director removal, adjournment procedures, and emergency bylaws (effective 2023-03-28).
“On March 28, 2023, in connection with a periodic review of the Composite Amended and Restated Bylaws, as amended, of Savara Inc. (“Savara”), the Board of Directors (the “Board”) of Savara adopted and approved Savara’s Amended and Restated Bylaws (the “Amended Bylaws”), which became immediately effective.”
Savara Inc amended Amendment with 1717 OSSRE, LLC (effective 2023-02-28).
“On February 28, 2023, Savara Inc. (“Savara”) entered into an amendment (the “Amendment”) to the Agreement of Lease, dated July 7, 2021, between Savara and 1717 OSSRE, LLC (the “Lease”) in order to increase the size of Savara’s offices in Langhorne, PA.”
Robert Lutz was appointed as Chief Operating Officer at Savara Inc.
“On February 13, 2023 (the “Effective Date”), Robert Lutz joined Savara Inc. (“Savara”) as its Chief Operating Officer.”
Dave Lowrance was appointed as Chief Financial and Administrative Officer at Savara Inc.
“On the Effective Date, the Board of Directors (the “Board”) of Savara appointed Dave Lowrance, who has served as Savara’s Chief Financial Officer since November 2016, as Chief Financial and Administrative Officer of Savara.”
Dr. Badrul Chowdhury resigned as Chief Medical Officer at Savara Inc.
“On August 24, 2022, Dr. Badrul Chowdhury notified Savara Inc. (“Savara”) of his decision to resign as Chief Medical Officer of Savara.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.